Current Evaluation and Treatment of Nocturia

다국어 초록 (Multilingual Abstract)

Nocturia is usually considered to be just one of the symptoms included with lower urinary tract symptoms (LUTS) and is treated with therapy based on LUTS. Recent research suggests, however, that nocturia is not merely a simple symptom of LUTS but is a multifactorial condition with many contributing etiological factors. The causes of nocturia can be classified into bladder storage problems, increased urine output, sleep disturbance problems, and other potential diseases. The frequency-volume chart (FVC) is very important in evaluating and diagnosing nocturia. Patients usually record the volume and timing of voids for a period of 1 to 3 days on the FVC. The FVC data can provide information on voiding patterns and clues about the etiology and treatment of nocturia. It is doubtful that alpha-blockers will have clinical significance for treatment because the difference in nocturia episodes between treatment with alpha-blockers and placebo is too small. Antimuscarinics also exert no effect on nocturnal polyuria, and the evidence supporting the efficacy of antimuscarinics for the treatment of nocturia is limited. However, several randomized placebo-controlled trials have shown the efficacy of oral desmopressin in the treatment of adults with nocturia. Short-acting hypnotics may be helpful for patients with sleep disturbances. Although surgical or interventional therapy is not indicated for nocturia, transurethral resection of the prostate appears to confer a greater improvement in benign prostatic hyperplasia symptoms including nocturia. The management of nocturia may require a team approach by making optimal use of multidisciplinary expertise.

참고문헌 (Reference)

1 Lukacz ES, "Urinary frequency in community-dwelling women: what is normal?" 200 : 552.e1-552.e7, 2009

2 Antunes AA, "Transurethral resection of the prostate for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: how much should be resected?" 35 : 683-689, 2009

3 van Kerrebroeck P, "The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society" 21 : 179-183, 2002

4 Coyne KS, "The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA" 92 : 948-954, 2003

5 Bosch JL, "The prevalence and causes of nocturia" 184 : 440-446, 2010

6 Djavan B, "The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study" 4 : 61-68, 2005

7 Kang SH, "The impact of sleep apnoea syndrome on nocturia according to age in men" 110 (110): E851-E856, 2012

8 Weiss JP, "The evaluation and treatment of nocturia: a consensus statement" 108 : 6-21, 2011

9 Endeshaw YW, "Sleep-disordered breathing and nocturia in older adults" 52 : 957-960, 2004

10 Cho SY, "Short-term effects of systematized behavioral modification program for nocturia: a prospective study" 31 : 64-68, 2012

11 Hunter DJ, "Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older" 155 : 1965-1970, 1996

12 Bing MH, "Prevalence and bother of nocturia, and causes of sleep interruption in a Danish population of men and women aged 60-80 years" 98 : 599-604, 2006

13 Irwin DE, "Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study" 50 : 1306-1314, 2006

14 Andersson KE, "Pharmacological treatment of urinary incontinence, In Incontinence" Health Publication Ltd 631-699, 2009

15 Brubaker L, "Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms" 18 : 737-, 2007

16 Kaye M, "Nocturia: a blinded, randomized, parallel placebo-controlled self-study of the effect of 5 different sedatives and analgesics" 2 : 604-608, 2008

17 Tikkinen KA, "Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland" 57 : 488-496, 2010

18 Yoshimura K, "Nocturia and benign prostatic hyperplasia" 61 : 786-790, 2003

19 Lose G, "Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women" 189 : 1106-1113, 2003

20 Rackley R, "Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia" 67 : 731-736, 2006

21 National Institute for Health and Clinical Excellence, "NICE clinical guideline 97. Lower urinary tract symptoms: the management of lower urinary tract symptoms in men" National Institute for Health and Clinical Excellence

22 Rudy D, "Multicenter phase III trial studying trospium chloride in patients with overactive bladder" 67 : 275-280, 2006

23 Yalkut D, "Mechanism of atrial natriuretic peptide release with increased inspiratory resistance" 128 : 322-328, 1996

24 Mattiasson A, "Efficacy of desmopressin in the treatment of nocturia: a double- blind placebo-controlled study in men" 89 : 855-862, 2002

25 Speakman M, "Efficacy and safety of Tamsulosin OCAS" 98 (98): 13-17, 2006

26 Rembratt A, "Differences between nocturics and non-nocturics in voiding patterns: an analysis of frequency-volume charts from community-dwelling elderly" 91 : 45-50, 2003

27 van Kerrebroeck P, "Desmopressin in the treatment of nocturia: a double- blind, placebo-controlled study" 52 : 221-229, 2007

28 Margel D, "Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea" 67 : 974-977, 2006

29 Nishino Y, "Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study" 97 : 747-751, 2006

30 Herschorn S, "Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo- controlled trial" 105 : 58-66, 2010

31 Lose G, "Clinical experiences with desmopressin for long-term treatment of nocturia" 172 : 1021-1025, 2004

32 Johnson TM 2nd, "Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial" 170 : 145-148, 2003

33 Fitzgerald MP, "BACH Survey Investigators. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey" 177 : 1385-1389, 2007

34 Cho MC, "Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study" 73 : 549-553, 2009

35 Reynard JM, "A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo" 81 : 215-218, 1998

36 Cornu JN, "A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management: a systematic review and meta-analysis" 62 : 877-890, 2012